PARDES BIOSCIENCES, INC.

Pardes Biosciences, Inc. (Nasdaq: PRDS) is a clinical-stage biopharmaceutical company focused on developing antiviral therapies, most notably for COVID-19. The company went public in 2021 through a business combination with FS Development Corp. II, a special purpose acquisition company sponsored by Foresite Capital Management. Pardes filed its 10-Q with the SEC on August 16, 2021, covering activity as a newly public entity in the biotechnology sector. The company has been advancing its lead oral antiviral program targeting the SARS-CoV-2 main protease. For complete filing history, deal terms, sponsor background, and real-time SPAC analytics on PRDS and hundreds of other vehicles, sign up for full data access at SpacDesk.